GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Cash from Discontinued Operating Activities

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Merrimack Pharmaceuticals's Cash from Discontinued Operating Activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Merrimack Pharmaceuticals received $0.00 Mil from discontinued investing activities. Merrimack Pharmaceuticals's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


Merrimack Pharmaceuticals Cash from Discontinued Operating Activities Historical Data

The historical data trend for Merrimack Pharmaceuticals's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Cash from Discontinued Operating Activities Chart

Merrimack Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merrimack Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Merrimack Pharmaceuticals Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merrimack Pharmaceuticals Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.


Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
Eric Andersen director, other: See Remarks 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker director, officer: President MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy director, other: See Remarks 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic director 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p. other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc other: See Remarks 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc. 10 percent owner, other: See Explanation of Responses 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Headlines

From GuruFocus

Merrimack Reports First Quarter 2019 Financial Results

By PRNewswire PRNewswire 05-10-2019

Merrimack Reports Full Year 2020 Financial Results

By Business Wire Business Wire 03-11-2021

Merrimack Discontinues Development of MM-310

By PRNewswire PRNewswire 04-05-2019

Merrimack Reports Full Year 2021 Financial Results

By Business Wire Business Wire 03-09-2022

Merrimack Reports Second Quarter 2022 Financial Results

By Business Wire Business Wire 08-04-2022

JFL Capital Issues Letter to Fellow Merrimack Stockholders

By PRNewswire PRNewswire 08-22-2019

Merrimack Reports Third Quarter 2022 Financial Results

By Business Wire Business Wire 11-03-2022

Merrimack Declares $20 Million Special Dividend

By PRNewswire PRNewswire 07-25-2019